

RESPIRATION DAY

CHRONIC AIRWAY DISEASES AND THEIR COMORBIDITIES

Fad Asincrona

30 Giugno – 31 Dicembre 2026

RAZIONALE SCIENTIFICO

The aim of the 2026 Edition of "Respiration Day" is to provide the view of where the Respiratory clinicians and researchers are and where they are heading in the field of chronic respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis and their comorbidities, and the role of small airway diseases in these respiratory diseases. The invited members of the Faculty are among the most productive international clinical scientists in the field chronic airway diseases, the audience will be 350 national top national clinical opinion leaders selected from more than 20 countries. The main aim of the meeting is educational, and the speakers have been specifically invited to translate in their lectures the most important recent discoveries to the potential improvement of clinical practice. A significant proportion of time (40%) will be devoted to discussion. The Meeting is divided in 5 sessions.

The first session will focus on the recent advancements in COPD and its comorbidities, and in particular the first lecture will focus on the need to better characterize the different phenotypes included under the umbrella of the term COPD, both in term of etiology and clinical presentation, early diagnosis, and active search of multimorbidity to improve the management of individual patients (Bhatt et al, 2025; Celli et al, 2022). The second lecture will be devoted to novel therapies for COPD, particularly the biologics, with the aim of improved comprehensive and personalized management (Agusti et al, 2025). The third lecture will focus on the major cardiovascular risk in patients with COPD, both in stable and during and in the aftermath of exacerbations of respiratory symptoms (Gale et al, 2025).

The second session will focus on asthma as a disease of both central and peripheral airways (Siddiqui et al, 2026), the need of integration of traditional pharmacological inhalation treatments with systemic agents and/or biologics (Porsbjerg et al, 2023), the third the ongoing research focused on mechanisms rather than clinical treatable traits (Gaberino et al, 2026).

The third session will be devoted to the importance and impact of small airways dysfunction for chronic airway diseases, and in particular on the fundamental role of inhalers but also of their environmental impact, its complex impact on respiratory and non-respiratory components of chronic airway diseases, and last, but not least, how can AI help us to understand the role of small airways dysfunction.

The fourth session will be devoted to the novel discoveries in the field of pathology of chronic airway diseases, and particularly the importance of mucus plugs, and mucociliary clearance.

Finally the fifth session will be devoted to bronchiectasis that in the last 15 years has been discovered to represent not only a treatable trait of other chronic airway diseases but also an independent treatable disease (Burgel and Mall, 2026; Chalmer et al, 2025).

PROGRAMMA

Modulo 1 Chronic obstructive pulmonary disease (COPD) as pulmonary component of multimorbidity

- 25' Novel approaches to the diagnosis and assessment of severity of multimorbid COPD - Surya Bhatt (Birmingham)
- 25' Novel approaches to the pharmacologic management of multimorbid COPD – Bartolome Celli (Boston)
- 25' Cardiovascular risk in stable and exacerbated multimorbid COPD - Filippo Crea (Rome)

Modulo 2 Asthma as a disease of central and peripheral airways

- 25' Pulmonary pathology of asthma, COPD and chronic bronchitis: role of small airways – Guy Brusselle (Ghent)
- 25' Integrated pharmacologic and biologic treatment of severe asthma
Matteo Bonini (Rome)
- 25' Mechanism directed treatment in chronic airway diseases - Klaus Rabe (Kiel)

Modulo 3 Small airways dysfunction in chronic airway diseases

25' Early origins of asthma: What happens to the airways? – Erika Von Mutius (Munich/Boston)

25' Pathophysiology of small airway diseases (SAD) – Omar Usmani (London)

25' Artificial intelligence in chronic airway diseases – Alvar A Agusti (Barcelona)

Modulo 4 Mucus and mucociliary clearance in chronic airway diseases

25' Clinical role of central and peripheral airway diseases in asthma - Maarten Van den Berge (Groningen)

25' Mucus plugs in chronic airway diseases - Alejandro A. Diaz (Boston)

25' The pathobiology and treatment of mucus plugs in asthma and COPD - John Fahy (San Francisco)

Modulo 5 Bronchiectasis as treatable trait of chronic airway diseases or as an independent disease entity

25' Novel approaches to the diagnosis and assessment of severity of bronchiectasis - Stefano Aliberti (Milan)

25' Novel approaches to the pharmacologic management of bronchiectasis – Michal Shteinberg (Haifa)

25' Mechanism directed treatment approach: triple therapy in cystic fibrosis - Pierre Regis Burgel (Paris)

ACRONIMI:

COPD: Chronic obstructive pulmonary disease

SAD: Small airway diseases

ECM

ID PROVIDER: 246

ID EVENTO:

CREDITI ASSEGNATI:

ORE ATTIVITÀ DIDATTICA: **6h25** – 7

PARTECIPANTI: 500

PIATTAFORMA EROGAZIONE:

SEGRETERIA ORGANIZZATIVA E PROVIDER:

DOC CONGRESS Srl - ID 246 Albo Provider Agenas

Via Dante Alighieri, 153 – 20099 Sesto San Giovanni (MI)

Tel: +39 02 244491- Fax: +39 02 24449227

www.doc-congress.com

RESPONSABILI SCIENTIFICI:

DARIO OLIVIERI

GAETANO CARAMORI